Sublocade® (buprenorphine extended-release) – Updated indication
February 24, 2025 - Indivior announced the FDA approval of Sublocade (buprenorphine extended-release), for the treatment of moderate to severe opioid use disorder (OUD) in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine.
Top